Aug 17, 2026 · 5 min
Anthropic lifts SanDisk as EyePoint and Snap lose ground
Sandisk Gains, EyePoint Tumbles, Snap Sinks on Court Ruling
The episode shows how company-specific catalysts—from AI-linked revenue to trial failures, insider selling, and litigation—can drive sharply different stock moves.
- 1SanDisk rises after preliminary revenue reports tied to Anthropic’s strong growth strengthen the AI-linked investment story.
- 2EyePoint plunges after a late-stage clinical trial fails, exposing the concentrated risk facing biotechnology companies.
- 3Snap declines amid insider selling and a pivotal court ruling that adds legal pressure to its market outlook.
Don't miss
EyePoint’s dramatic plunge after a failed late-stage clinical trial is the episode’s clearest example of a single catalyst overwhelming a stock.
The brief
Stock Movers opens with a market-movers roundup built around three contrasting cases: SanDisk’s rise, EyePoint’s plunge, and Snap’s decline.
Judy Lagrou joins Paul Sweeney to connect SanDisk’s gains to strong preliminary revenue reports from Anthropic, underscoring how AI growth can affect adjacent companies.
EyePoint provides the sharpest downside example: a failed late-stage clinical trial sends the biopharmaceutical company into a dramatic plunge.
Snap’s weakness has a different mix of causes, with insider selling and a pivotal court ruling adding pressure to the technology company.
Together, the moves show why stock reactions depend less on a shared market mood than on the specific catalyst confronting each company.
What was said on this episode
3 statements · 3 negative
Snap is set to break its winning streak.
“the social media company is set to break their winds streak”
Listen at 2:35
Snap’s stock has declined about 33% this year.
“The stock is down about 33% this year.”
Listen at 2:44
Social media platforms like Snap have been addictive and deceptive to young internet users.
“they have been quite addictive and deceiving to young Internet users”
Listen at 2:57
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
EyePoint Pharmaceuticals, Inc.
SanDisk
Anthropic
Stock MarketListen to the full episode and explore every guest, topic, and moment on PodLume.